** AUBAGIO® (teriflunomide) 14 mg 28 film-coated tablets. Oral use.
Each tablet contains:
14 mg teriflunomide.
Also contains: lactose. See leaflet for further information.
** Therapeutic indications:
AUBAGIO is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS).
** Pharmacotherapeutic group:
Selective immunosuppressants, ATC Code: L04AA31.
** Mechanism of action:
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), required for the de novo pyrimidine synthesis. As a consequence teriflunomide reduces the proliferation of dividing cells that need de novo synthesis of pyrimidine to expand. The exact mechanism by which teriflunomide exerts its therapeutic effect in multiple sclerosis is unknown but may involve a reduction in the number of activated lymphocytes in CNS.
** Read the package leaflet before use.
Medicinal product subject to medical prescription. POM
** Keep out of the sight and reach of children.
** Genzyme (A Sanofi Company)
54, rue La Boetie
F – 75008 Paris